Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER Metastatic Breast Cancer.

Authors:
Pingping Mao Ofir Cohen Kailey J Kowalski Justin G Kusiel Jorge E Buendia-Buendia Michael S Cuoco Pedro Exman Seth A Wander Adrienne G Waks Utthara Nayar Jon Chung Samuel Freeman Orit Rozenblatt-Rosen Vincent A Miller Federica Piccioni David E Root Aviv Regev Eric P Winer Nancy U Lin Nikhil Wagle

Clin Cancer Res 2020 Nov 28;26(22):5974-5989. Epub 2020 Jul 28.

Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.

Purpose: To identify clinically relevant mechanisms of resistance to ER-directed therapies in ER breast cancer.

Experimental Design: We conducted a genome-scale functional screen spanning 10,135 genes to investigate genes whose overexpression confer resistance to selective estrogen receptor degraders. In parallel, we performed whole-exome sequencing in paired pretreatment and postresistance biopsies from 60 patients with ER metastatic breast cancer who had developed resistance to ER-targeted therapy. Furthermore, we performed experiments to validate resistance genes/pathways and to identify drug combinations to overcome resistance.

Results: Pathway analysis of candidate resistance genes demonstrated that the FGFR, ERBB, insulin receptor, and MAPK pathways represented key modalities of resistance. The FGFR pathway was altered via , or amplifications or mutations in 24 (40%) of the postresistance biopsies. In 12 of the 24 postresistance tumors exhibiting FGFR/FGF alterations, these alterations were acquired or enriched under the selective pressure of ER-directed therapy. experiments in ER breast cancer cells confirmed that FGFR/FGF alterations led to fulvestrant resistance as well as cross-resistance to the CDK4/6 inhibitor palbociclib. RNA sequencing of resistant cell lines demonstrated that FGFR/FGF induced resistance through ER reprogramming and activation of the MAPK pathway. The resistance phenotypes were reversed by FGFR inhibitors, a MEK inhibitor, and/or a SHP2 inhibitor.

Conclusions: Our results suggest that FGFR pathway is a distinct mechanism of acquired resistance to ER-directed therapy that can be overcome by FGFR and/or MAPK pathway inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-3958DOI Listing
November 2020

Publication Analysis

Top Keywords

breast cancer
12
resistance
11
fgfr/fgf alterations
8
estrogen receptor
8
postresistance biopsies
8
metastatic breast
8
resistance er-directed
8
confer resistance
8
er-directed therapy
8
mapk pathway
8
fgfr pathway
8
pathway
5
fgfr
5
40% postresistance
4
mutations 40%
4
amplifications mutations
4
pathway altered
4
altered amplifications
4
resistance fgfr
4
tumors exhibiting
4

Altmetric Statistics


Show full details
4 Total Shares
4 Tweets
4 Citations

Similar Publications

Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8 T cell-mediated antitumor responses in mice.

Authors:
Jianhua Pan Meng Ma Li Qin Zhongkui Kang Dickson Adah Zhu Tao Xiaofen Li Linglin Dai Siting Zhao Xiaoping Chen Qin Zhou

Biomed Pharmacother 2021 Mar 3;138:111406. Epub 2021 Mar 3.

The Ministry of Education Key Laboratory of Laboratory Medical Diagnostics, the College of Laboratory Medicine, Chongqing Medical University, 1st Yixueyuan Road, 400016 Chongqing, China. Electronic address:

We previously reported that Plasmodium infection promotes antitumor immunity in a murine Lewis lung cancer. In this study, we investigated the effects of Plasmodium infection on the tumor inhibition and antitumor CD8 T cell responses in a murine triple negative breast cancer (TNBCA) model. The results showed that Plasmodium infection significantly inhibited tumor growth, and increased the survival rate of the tumor-bearing mice. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.

Authors:
C Corti C Criscitiello

ESMO Open 2021 Mar 3;6(2):100063. Epub 2021 Mar 3.

Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy. Electronic address:

View Article and Full-Text PDF
March 2021
Similar Publications

Identification of U83836E as a γ-glutamylcyclotransferase inhibitor that suppresses MCF7 breast cancer xenograft growth.

Authors:
Hiromi Ii Yukie Nohara Taku Yoshiya Shun Masuda Shugo Tsuda Shinya Oishi Jonathan Friedman Takumi Kawabe Susumu Nakata

Biochem Biophys Res Commun 2021 Mar 3;549:128-134. Epub 2021 Mar 3.

Department of Clinical Oncology, Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashina, Kyoto, 607-8414, Japan. Electronic address:

γ-Glutamylcyclotransferase (GGCT) is involved in glutathione homeostasis, in which it catalyzes the reaction that generates 5-oxoproline and free amino acids from γ-glutamyl peptides. Increasing evidence shows that GGCT has oncogenic functions and is overexpressed in various cancer tissues, and that inhibition of GGCT activity exerts anticancer effects in vitro and in vivo. Here, we demonstrate that U83836E ((2R)-2-[[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]methyl]-3,4-dihydro-2,5,7,8,-tetramethyl-2H-1-benzopyran-6-ol, dihydrochloride), a lazaroid that inhibits lipid peroxidation, inhibits GGCT enzymatic activity. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

"The use of bisphosphonates to treat skeletal complications in solid tumours".

Authors:
S D'Oronzo- S Wood- J E Brown-

Bone 2021 Mar 3:115907. Epub 2021 Mar 3.

Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, University of Sheffield, Weston Park Hospital, Whitham Rd, Broomhill, Sheffield S10 2SJ, UK.

The skeleton is the most common site of secondary disease in breast cancer and prostate cancer, with up to 80% of patients with advanced disease developing bone metastases (BM). The proportion is also substantial in advanced lung cancer (20% - 40%). Because of the high prevalence of cancers of the breast, prostate and lung, these cancers account for more than 80% of cases of metastatic bone disease occurring in solid tumours. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

3,7-bis-benzylidene hydrazide ciprofloxacin derivatives as promising antiproliferative dual TOP I & TOP II isomerases inhibitors.

Authors:
Mohamed Samir Mohamed Ramadan Mostafa H Abdelrahman Mahmoud S Abdelbaset Mohammed A S Abourehab Mohamed Abdel-Aziz Gamal El-Din A Abuo-Rahma

Bioorg Chem 2021 Feb 15;110:104698. Epub 2021 Feb 15.

Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Deraya University, New Minia, Minia, Egypt. Electronic address:

We report herein design and synthesis of a new series of 3,7-bis-benzylidenes of ciprofloxacin. Most of the target compounds revealed good cytotoxic activity; the most potent 4e and 4i achieved strong broad spectrum antiproliferative activity with comparable activity to Doxorubicin with IC (M) of 1.21 ± 0. Read More

View Article and Full-Text PDF
February 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap